Itoh S, Yoshizumi T, Yugawa K, Imai D, Yoshiya S, Takeishi K, et al. Impact of immune response on outcomes in hepatocellular carcinoma: association with vascular formation. Hepatology. 2020;72(6):1987–99.

CAS  Article  Google Scholar 

European Association for the Study of the Liver. EASL clinical practice guidelines: management of hepatocellular carcinoma. J Hepatol. 2018;69(1):182–236.

Article  Google Scholar 

El-Serag HB, Rudolph KL. Hepatocellular carcinoma: epidemiology and molecular carcinogenesis. Gastroenterology. 2007;132:2557–76.

CAS  Article  Google Scholar 

Itoh S, Morita K, Ueda S, Sugimachi K, Yamashita Y, Gion T, et al. Long-term results of hepatic resection combined with intraoperative local ablation therapy for patients with multinodular hepatocellular carcinomas. Ann Surg Oncol. 2009;16(12):3299–307.

Article  Google Scholar 

Llovet JM, Ricci S, Mazzaferro V, Hilgard P, Gane E, Blanc JF, et al. Sorafenib in advanced hepatocellular carcinoma. N Engl J Med. 2008;359:378–90.

CAS  Article  Google Scholar 

Schlumberger M, Tahara M, Wirth LJ, Robinson B, Brose MS, Elisei R, et al. Lenvatinib versus placebo in radioiodine-refractory thyroid cancer. N Engl J Med. 2015;372:621–30.

Article  Google Scholar 

Motzer RJ, Hutson TE, Glen H, Michaelson MD, Molina A, Eisen T, et al. Lenvatinib, everolimus, and the combination in patients with metastatic renal cell carcinoma: a randomised, phase 2, open-label, multicentre trial. Lancet Oncol. 2015;16:1473–82.

CAS  Article  Google Scholar 

Kudo M, Finn RS, Qin S, Han K, Ikeda K, Piscaglia F, et al. Lenvatinib versus sorafenib in first-line treatment of patients with unresectable hepatocellular carcinoma: a randomised phase 3 non-inferiority trial. Lancet. 2018;391(10126):1163–73.

CAS  Article  Google Scholar 

Suzuki T, Yamamoto A, Ohsawa M, Motoo Y, Mizukami H, Makino T. Ninjin’yoeito and ginseng extract prevent oxaliplatin-induced neurodegeneration in PC12 cells. J Nat Med. 2015;69:531–7.

CAS  Article  Google Scholar 

Ohsawa M, Maruoka J, Inami C, Iwaki A, Murakami T, Ishikura K, et al. Effect of ninjin’yoeito on the loss of skeletal muscle function in cancer-bearing mice. Front Pharmacol. 2018;9:1400.

CAS  Article  Google Scholar 

Miyano K, Nonaka M, Uzu M, Ohshima K, Uezono Y. Multifunctional actions of Ninjinyoeito, a Japanese kampo medicine: accumulated scientific evidence based on experiments with cells and animal models, and clinical studies. Front Nutr. 2018;5:93.

Article  Google Scholar 

Suzuki T, Yamamoto A, Ohsawa M, Motoo Y, Mizukami H, Makino T. Effect of ninjin’yoeito and ginseng extracts on oxaliplatin-induced neuropathies in mice. J Nat Med. 2017;71:757–64.

CAS  Article  Google Scholar 

Kaibori M, Ishizaki M, Matsui K, Kwon M, Imai R, Watanabe S, et al. Sorafenib alone versus a combination of sorafenib and ninjin’yoeito for the treatment of patients with advanced hepatocellular carcinoma: a retrospective study and pharmacological study in rats. J Tradit Med. 2013;30:221–8.

CAS  Google Scholar 

Heimbach JK, Kulik LM, Finn RS, Sirlin CB, Abecassis MM, Roberts LR, et al. AASLD guidelines for the treatment of hepatocellular carcinoma. Hepatology. 2018;67(1):358–80.

Article  Google Scholar 

Kokudo N, Hasegawa K, Akahane M, et al. Evidence-based clinical practice guidelines for hepatocellular carcinoma. The Japan Society of Hepatology 2013 update (3rd JSH–HCC Guidelines). Hepatol Res. 2015;45(2):123–7.

Johnson PJ, Berhane S, Kagebayashi C, Satomura S, Teng M, Reeves HL, et al. Assessment of liver function in patients with hepatocellular carcinoma: a new evidence-based approach-the ALBI grade. J Clin Oncol. 2015;33(6):550–8.

Article  Google Scholar 

Hiraoka A, Michitaka K, Kumada T, Izumi N, Kadoya M, Kokudo N, et al. Validation and potential of albumin-bilirubin grade and prognostication in a nationwide survey of 46, 681 hepatocellular carcinoma patients in Japan: the need for a more detailed evaluation of hepatic function. Liver Cancer. 2017;6(4):325–36.

CAS  Article  Google Scholar 

Hryniuk W, Bush H. The importance of dose intensity in chemotherapy of metastatic breast cancer. J Clin Oncol. 1984;2(11):1281–8.

CAS  Article  Google Scholar 

Levin L, Hryniuk WM. Dose intensity analysis of chemotherapy regimens in ovarian carcinoma. J Clin Oncol. 1987;5(5):756–67.

CAS  Article  Google Scholar 

Kawashima A, Takayama H, Arai Y, Tanigawa G, Nin M, Kajikawa J, et al. One-month relative dose intensity of not less than 50% predicts favourable progression-free survival in sorafenib therapy for advanced renal cell carcinoma in Japanese patients. Eur J Cancer. 2011;47:1521–6.

CAS  Article  Google Scholar 

Hosseinzadeh H, Nassiri-Asl M. Pharmacological effects of glycyrrhiza spp. and its bioactive constituents: update and review. Phytother Res. 2015;29:1868–86.

Article  Google Scholar 

Cyong JC, Ki SM, Iijima K, Kobayashi T, Furuya M. Clinical and pharmacological studies treated with kampo herbal medicine. Am J Chin Med. 2000;28:351–60.

CAS  Article  Google Scholar 

Matsuki R, Kawai K, Suzuki Y, Kogure M, Nakazato T, Naruge D, et al. Pathological complete response in conversion hepatectomy induced by lenvatinib for advanced hepatocellular carcinoma. Liver Cancer. 2020;9(3):358–60.

Article  Google Scholar 

Adam R, Wicherts DA, de Haas RJ, Ciacio O, Lévi F, Paule B, et al. Patients with initially unresectable colorectal liver metastases: is there a possibility of cure? J Clin Oncol. 2009;27:1829–35.

Article  Google Scholar 

Sato Y, Ohnuma H, Nobuoka T, Hirakawa M, Sagawa M, Fujikawa K, et al. Conversion therapy for inoperable advanced gastric cancer patients by docetaxel, cisplatin, and S-1 (DCS) chemotherapy: a multi-institutional retrospective study. Gastric Cancer. 2017;20:517–26.

CAS  Article  Google Scholar 

Ohya Y, Hayashida S, Tsuji A, Kuramoto K, Shibata H, Setoyama H, et al. Conversion hepatectomy for advanced hepatocellular carcinoma after right portal vein transection and lenvatinib therapy. Surg Case Rep. 2020;6(1):318.

Article  Google Scholar 

Fagenson AM, Gleeson EM, Pitt HA, Lau KN. Albumin-bilirubin score vs. model for end-stage liver disease in predicting post-hepatectomy outcomes. J Am Coll Surg. 2020;230(4):637–45.

Article  Google Scholar 

Andreatos N, Amini N, Gani F, Margonis GA, Sasaki K, Thompson VM, et al. Albumin–Bilirubin Score: predicting short-term outcomes including bile leak and post-hepatectomy liver failure following hepatic resection. J Gastrointest Surg. 2017;21(2):238–48.

Article  Google Scholar